Garheng has served as chairman of our board of directors since July 2020. He previously served as lead independent director from November 2019 to July 2020 and has been a member of our board of directors since September 2015. In July 2013, he founded and has since served as managing partner of, HealthQuest Capital, a healthcare venture growth fund. He brings over 20 years of clinical, technical, and business experience in creating and building high-growth and innovation-based healthcare businesses. He currently serves on the board of directors of Venus Concept, Alimera Sciences, Inc., and Laboratory Corporation of America Holdings. Garheng previously served on the board of directors of Histogenics Corporation, and Avedro, Inc. Garheng’s early career included positions at GlaxoSmithKline, McKinsey, and TherOx before he started his investing career.
Garheng earned his MD, PhD, and MBA from Duke University and received a BS in chemical engineering and a BS in biological sciences from Stanford University.
Throughout his career, David has served in a number of corporate officer roles and as a director of various publicly traded life sciences companies. He served as the president and chief financial officer of EndoChoice, a public medical device company focused on gastrointestinal disease, from April 2016 through the sale of the company to Boston Scientific in November 2016, and as chief financial officer from August 2014 to November 2016. Prior to Endochoice, David served as chief financial officer of INC Research Holdings Inc., now known as Syneos, after serving as a board member and audit committee chairman of the company. Earlier in his career he served in senior leadership roles for several medical device companies including TransEnterix, NxStage Medical, CTI Molecular Imaging, Inc., Novoste Corporation and Dornier Medical. David currently serves on the board of directors of Evolus, Inc. and Y-mAbs Therapeutics, Inc. He has led initial public offerings for four companies and has raised more than $1.2 billion in equity and debt over his career.
David holds a BS degree, cum laude, in accounting from Wake Forest University and an MBA degree, with honors, from Emory University, and he was formerly a certified public accountant.
John was appointed to chief executive officer in July 2020. He previously served as executive chairman from November 2019 to July 2020 and as chairman from March 2015 to November 2019. He is a recognized leader in the biopharmaceutical industry with more than 30 years of experience at leading global organizations, including Johnson & Johnson, Eli Lilly & Company, ImClone, and Pfizer, Inc. He currently serves as a member of the board of directors of Verastem, Inc. John previously served on the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA), the Health Section Governing Board of Biotechnology Industry Organizations (BIO), and BioNJ.
John holds a BS from the East Stroudsburg University of Pennsylvania.
Jeff currently serves as chief medical officer and executive vice president at Horizon Therapeutics plc and has served as a member of our board of directors since October 2016. He brings more than 25 years of research, clinical development, regulatory and commercialization experience within the biopharmaceutical industry. Jeff also serves on the board of directors at Xeris Pharmaceuticals, Inc. He is a member of a number of professional societies, and a diplomate of the National Board of Medical Examiners and the American Board of Internal Medicine, and he also serves on the Board of Advisors of the Center for Information and Study on Clinical Research Participation (CISCRP). He previously held senior leadership positions at IDM Pharma, Takeda Global Research and Development, NeoPharm, Searle/Pharmacia, and Bristol-Myers Squibb. He is a past president of the Drug Information Association (DIA) and serves as DIA liaison to the FDA Clinical Trial Transformation Initiative (CTTI).
Jeff earned his MD from the Rosalind Franklin University of Medicine and Science/The Chicago Medical School. He completed internship, residency, and chief residency in internal medicine at Northwestern University Feinberg School of Medicine, where he currently serves as an adjunct assistant professor and a member of the alumni board, and a fellowship program in infectious diseases at the University of California San Francisco, where he was also a research associate at the Howard Hughes Medical Institute in allergy and immunology. He received a BA in Biology from Lake Forest College.
Mårten has served as a member of our board of directors since December 2014. Since April 2010, he has served as a Partner of HealthCap VI LP, a venture capital firm investing in life science companies. Prior to HealthCap, from February 2008 until March 2010, Mårten served as director at Merck Serono SA, a biopharmaceutical company. He previously served on the boards of Ultragenyx Pharmaceutical, Inc.; Wilson Therapeutics AB; Altimmune, Inc.; and FerroKin Biosciences.
Mårten holds an MD and a PhD in clinical chemistry and a BSc in business administration, all from Lund University.
Hilde has served as a member of our board of directors since January 2014. She is currently chief executive officer at Staten Biotechnology, an early-stage company developing a human monoclonal antibody with a unique approach toward neutralizing apoC3, a key molecule in dyslipidemia management. She also serves as chief operations officer and co-founder of NorthSea Therapeutics B.V., a late-stage biopharmaceutical company with the lead candidate targeting NASH. Prior to joining Staten Biotechnology and NorthSea Therapeutics, Hilde served as head of strategic innovation management in the Nutrition and Health Division (EN), BASF, as well as head of global Omega-3 innovation management and head of investor relations for Pronova BioPharma. She is on the board of directors and acts as head of the Audit Committee of Nordic Nanovector ASA and director of PCI Biotech AS. She previously served as a member of the board of directors of Algeta ASA, Weifa AS, Invent2 AS, Alertis AS, Clavis Pharma ASA, and Biotech Pharmacon ASA.
Hilde holds an MSc in molecular biology/biotechnology and a PhD in medical biochemistry, both from the University of Oslo.
© 2020 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Dublin Limited and Strongbridge U.S. Inc.
KEVEYIS® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.
MLR-0010 V18 05/2020